970*90
768
468
mobile

Suven Life gets patents from Norway, South Korea, Singapore

Franchise India Bureau
Franchise India Bureau Mar 22 2018 - 1 min read
Suven Life gets patents from Norway, South Korea, Singapore
The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers disease, attention deficient hyperactivity disorder (ADHD), etc

Suven Life Sciences has claimed to have been granted a patent each by Norway, South Korea and Singapore corresponding to new chemical entities (NCEs) for the treatment of disorders associated with neurodegenerative diseases.

As per the filing registered by the company, the patents are valid till 2027, 2034 and 2036, respectively.

Suven Life CEO Venkat Jasti said, "We are pleased by the grant of these patents to Suven for our pipeline of molecules in the CNS arena, which are being developed for cognitive disorders with high unmet medical need with a huge market potential globally.”

The granted claims of the patents are being developed as therapeutic agents and are useful in the treatment of cognitive impairment associated with neurodegenerative disorders like Alzheimers disease, attention deficient hyperactivity disorder (ADHD), Huntingtons disease, Parkinsons and Schizophrenia.

Suven Life Sciences shares were trading 1.77 per cent up at Rs 172.20 on BSE.

Subscribe Newsletter
Submit your email address to receive the latest updates on news & host of opportunities
Entrepreneur Magazine

For hassle free instant subscription, just give your number and email id and our customer care agent will get in touch with you

or Click here to Subscribe Online